Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03194698 · ClinicalTrials.gov registry record · NA
Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea
A NA study of Dry Eye and Ocular Rosacea, sponsored by Mayo Clinic.
- Completed
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT03194698 is a NA study of Dry Eye and Ocular Rosacea that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03194698, a NA study of Dry Eye and Ocular Rosacea, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
Dry eye disease (DED) is a common condition that causes ocular discomfort and reduces visual acuity. The two categories of DED are evaporative dry eye and aqueous deficient dry eye. Both conditions can involve pathology of the meibomian glands, lacrimal glands, lids, tear film and surface cells. Meibomian gland dysfunction (MGD) is the leading cause of evaporative dry eye and contributes to aqueous deficient dry eye. The goal of MGD therapy is to provide long term improvement of symptoms for patients by improving the quality of meibum, increasing meibum flow, improving tear film stability and decreasing inflammation. Commonly used therapies include preservative free drops, omega-3 fatty acid supplementation, topical cyclosporine, serum tears, topical azithromycin, oral doxycycline, moisture chambers, intraductal probing, lib margin exfoliation, automated thermal pulsation, warm compresses, among other. Despite this variety of symptoms, patients often do not experience complete or long term relief of symptoms. Forced meibomian gland expression (MGX) has been shown to be an effective method of rehabilitating meibomian glands and improving dry eye symptoms. The eyelid margins are forcefully compressed to express gland contents. Research has shown improvement in patient symptoms with the use of MGX. Intense pulsed light (IPL) have been used in dermatology to treat various conditions. Patients with DED who have tried other therapies and found no relief, often resort to IPL as a last resort. Research has shown IPL alone may be effective in improving patient symptoms. In addition, such studies have failed to show significant adverse events with the use of IPL. Here, we propose a prospective, randomized, case controlled clinical pilot study to examine the efficacy for both subjective and objective measures. 20 patients with DED will be recruited and will be randomly assigned to one of two groups: MGX alone or MGX with IPL. Objective measures will include tear cytokine l
Conditions Studied
Interventions
- DEVICE Intense Pulsed Light Treatment (IPL)
- PROCEDURE Meibomian Gland Expression
Study Locations (1)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-08-17 |
| Est. Completion | 2018-12-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03194698
The ClinicalTrials.gov registry entry for NCT03194698 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 41 other Dry Eye trials with a reported enrollment target (79% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Intense Pulsed Light Treatment (IPL) is the first listed.
NCT03194698 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT03194698 about?
NCT03194698 is a clinical study titled "Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea". Dry eye disease (DED) is a common condition that causes ocular discomfort and reduces visual acuity. The two categories of DED are evaporative dry eye and aqueous deficient dry eye. Both conditions can involve pathology of the meibomian glands, lacrimal glands, lids, tear film and surface cells. Mei...
What is the current status of trial NCT03194698?
This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2017-08-17. Estimated completion is 2018-12-06.
What conditions does trial NCT03194698 study?
This clinical trial studies the following conditions: Dry Eye, Ocular Rosacea.
What interventions are being tested in trial NCT03194698?
The interventions under investigation include: Intense Pulsed Light Treatment (IPL) (DEVICE), Meibomian Gland Expression (PROCEDURE).
Who is sponsoring clinical trial NCT03194698?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03194698 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The THINK Study Incidence of Neurotrophic Keratopathy)
RECRUITING · NA
-
Low Level Light Therapy & Skin Pigmentation
RECRUITING · NA
-
Corneal Epithelial Stem Cells and Dry Eye Disease
COMPLETED · NA
-
Acute Comfort of Lubricant Eye Drops FID 112903
COMPLETED · NA
-
Evaluation of Extended Tear Film Break Up Time (TFBUT) With an Ocular Emulsion
COMPLETED · NA
-
Intense Pulse Light Treatment With Meibomian Gland Expression of the Upper Eyelids in Dry Eye Disease
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.